ICE--an efficient drug combination for stem cell mobilization and high-dose treatment of malignant lymphoma.
Between 1989 and 1999 we studied the ICE regimen in sequential trials in 290 patients with malignant lymphoma and germ-cell tumours. For patients with relapsed or refractory lymphoma we could demonstrate a comparable efficacy of ICE to other high-dose chemotherapy (HDCT) regimens but with a toxicity profile in favour of ICE. From a retrospective comparative analysis of ICE as HDCT regimen in patients with malignant lymphoma and germ-cell tumours we conclude that the characteristic toxicity profile of ICE varies depending on prior drug exposure of individual patients. Further dose intensification of ICE may be achieved with acceptable toxicity by adding further drugs (e.g. anthracyclines) or by treatment with sequential cycles of ICE (Tandem-HDCT). More convenient drug formulations (e.g. etoposide phosphate) might further improve the therapeutic index of ICE.
Kingreen
D
D
Klinik für Innere Medizin m.S. Hämatologie/Onkologie Charité, Campus Virchow Klinikum Augustenburgerplatz 1 D-13353 Berlin, Germany. dorothea.kingreen@charite.de
Beyer
J
J
Kleiner
S
S
Reif
S
S
Huhn
D
D
Siegert
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000633:toxicity; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D015996:Survival Rate; D013810:Therapeutic Equivalency
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide